Discover Qazaqstan via News and Inspiring Stories
QazMonitor Logo
Facebook Qazmonitor iconInstagram Qazmonitor iconTiktok Qazmonitor iconTwitter Qazmonitor iconTelegram Qazmonitor iconYoutube Qazmonitor iconRSS
  1. Main Page
  2. News
  3. Turkish Companies Ready to Invest $60M in Kazakh Pharma
Astana, Kazakhstan • 19 May, 2022 | 06:20
1 min read

Turkish Companies Ready to Invest $60M in Kazakh Pharma

Atabay will produce various drugs in Kazakhstan, and Nobel Ilac to focus on oncology medicine

QazMonitor Logo
unsplash.com
unsplash.com

A new pharmaceutical enterprise is planned to be built in Almaty with the support of Turkish investors. This was announced by the Minister of Health of Kazakhstan Azhar Giniyat, Anadolu reports.

According to Giniyat, a corresponding agreement has been reached with a well-known Turkish company Atabay Kimya Sanayi Ticaret. The preliminary investments in the venture will amount to $10 million.

aa.com.tr
aa.com.tr

"Today it is a well-known pharmaceutical company in Turkey and Europe. Now it registers more than 20 types of drugs and is ready to produce these drugs in our country. We are talking about a variety of drugs: anti-inflammatory, antibiotics, painkillers,"

Azhar Giniyat

Giniyat said that another Turkish pharmaceutical company Nobel Ilac is ready to invest in Kazakhstan.

According to the Minister, they are talking about the development of medicines, as well as conducting clinical trials in order to produce drugs that are prescribed for cancer. "They are ready to invest more than $50 million in our country," said the minister.

Earlier it was reported that the head of Kazakhstan's Ministry of Health Azhar Giniyat discussed joint implementation of projects with leaders of several Turkish companies during the visit of President Kassym-Jomart Tokayev to Turkey.

The projects will be implemented in 2023 and 2025, respectively.

Only 30% of an article published on The Qazaqstan Monitor website may be used with a mandatory hyperlink provided to indicate the original source. To re-publish the full article, written permission from the editorial is required.